1Penn I. Incidence and treatment of neoplasia after transplantation. J Heart Lung Transplant, 1993,12 ( 6 Pt 2 ) : S328-336.
2Kenngott S, Gerbes AL, Schauer R, et al. Rapid development of esophageal squamous cell carcinoma after liver transplantation for alcohol-induced cirrhosis. Transpl Int,2003,16(9 ) :639-641.
3Penn I. Post-transplant malignancy:the role of immunosuppression.Drug Saf,2000,23 (2) :101-113.
4Penn I. Cancers in renal transplant recipients. Advances in Renal Replacement Therapy,2000,7 ( 2 ) : 147-156.
5Penn I, First MR. Merkel~ cell carcinoma in organ recipients:report of 41 cases. Transplantation, 1999,68 ( 11 ) : 1717-1721.
6Penn I. Occurrence of cancers in immunosuppressed organ transplant recipients. Clin Transpl, 1998,47 ( 1 ) : 147-158.
7Brivio F,Lissoni P, Rovelli F,et al. Effects of IL-2 preoperative immunotherapy on surgery-induced changes in angiogenic regulation and its prevention of VEGF increase and IL-12 decline. Hepatogastroenterology, 2002,49 ( 44 ) : 385-387.
8Guthery SL, Heubi JE, Bucuvalas JC, et al. Determination of risk factors for Epstein-Ban" virus-associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment. Transplantation, 2003,75 ( 7 ) :987-993.
9Newell KA, Alonso EM, Whitnggton PF, et al. Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Ban" virus infection and immunosuppression. Transplantation, 1996,62 ( 3 ) : 370-375.
10Stallone G, Schena A, Infante B,et al. Sirolimus for Kaposig sarcoma in renal-transplant recipients. N Engl J Med,2005,352 ( 13 ) :1317-1323.
